A novel presenilin 1 mutation (L174M) in a large Cuban family with early onset Alzheimer disease. by Marcheco Teruel, B. et al.
Abstract We studied a Cuban family with presenile de-
mentia (autosomal dominant) consisting of 281 members
within six generations, the proband descended from a
Spanish founder. Mean age at onset was 59 years of age.
Memory impairment was the main symptom in all pa-
tients, additionally, ischemic episodes were described in 4
(n=18) patients. Neuropathological examination of brain
material (1 patient) revealed neuronal loss, amyloid
plaques, and neurofibrillary tangles. Thirty DNA samples
were genotyped (regions on chromosome 1, 3, 10, 12, 14,
17, 19, 20, and 21). A maximum Lod score of 3.79 at θ=0
was obtained for marker D14S43, located in a 9-cM inter-
val in which all patients shared the same haplotype. Se-
quencing of the PSEN1 gene revealed a heterozygous
base substitution, C520A (exon 6), which is predicted to
cause an amino acid change from leucine to methionine
in the TMIII of the presenilin 1 protein. The mutation
was found to co-segregate with the disease phenotype and
the associated disease haplotype. The C→A change was
not observed in 80 control chromosomes from the Cuban
population. Leucine at position 174 is highly conserved
among species and is identical in presenilin 1 and presen-
ilin 2 proteins. We propose the L174 M mutation might
lead to an abnormal N-terminal and probably C-terminal
fragments and malfunction of the protein complex. In
conclusion, we found a novel PSEN1 mutation in a large
family with clinical and pathological diagnosis of early
onset familial Alzheimer disease, which may be relevant
for other Hispanic populations.
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Introduction
Alzheimer disease (AD, MIM 1043300) is the most
common type of dementia, characterized by progressive
memory loss and deterioration of cognitive functions, re-
sulting in a state of complete dependency, with severe
implications for patients, relatives, and caregivers.
The complex etiology of AD comprises both genetic and
environmental factors; sporadic and familial (FAD) forms
of the disease have been described. The high similarity in
clinical and neuropathological features between the early
onset familial and “sporadic” late-onset AD suggests that
similar pathophysiological factors are involved. Studies fo-
cusing on large families with the rare, early onset, autoso-
mal dominant form of the disease led to the discovery that
mutations in the amyloid precursor protein (APP) [1], pre-
senilin 1 (PSEN1) [2], and presenilin 2 (PSEN2) [3, 4]
genes cause AD. Although these autosomal dominant fami-
A.M. Bertoli Avella and B. Marcheco Teruel contributed equally
to this work. Disclosure: all experiments comply with the current
laws in The Netherlands.
A.M. Bertoli Avella (✉) · E.A. Severijnen · M. Joosse · P. Heutink
Department of Clinical Genetics, Erasmus Medical Center, 
Rotterdam, The Netherlands
Tel.: +31-10-4087387, Fax: +31-10-4089406
A.M. Bertoli Avella · C.M. van Duijn
Department of Epidemiology and Biostatistics, 
Erasmus Medical Center, Rotterdam, The Netherlands
A.M. Bertoli Avella · B. Marcheco Teruel · L. Heredero Baute
National Centre of Medical Genetics, 
Higher Institute of Medical Sciences, Havana, Cuba
J.J. Llibre Rodriguez
Department of Neurology, Carlos J. Finlay Hospital, Havana, 
Cuba
N. Gomez Viera
Department of Neurology, Hnos Ameijeiras Hospital, Havana, 
Cuba
I. Borrajero Martinez
Department of Pathology, Hnos Ameijeiras Hospital, Havana, 
Cuba
A.M. Bertoli Avella
Genetic Epidemiology Unit, 
Department of Epidemiology and Biostatistics, 
Erasmus Medical Center, P.O. Box 1738, 
3000 DR Rotterdam, The Netherlands
Neurogenetics (2002) 4:97–104
DOI 10.1007/s10048-002-0136-6
O R I G I N A L  A R T I C L E
A. M. Bertoli Avella · B. Marcheco Teruel
J. J. Llibre Rodriguez · N. Gomez Viera
I. Borrajero Martinez · E. A. Severijnen · M. Joosse
C. M. van Duijn · L. Heredero Baute · P. Heutink
A novel presenilin 1 mutation (L174 M) in a large Cuban family
with early onset Alzheimer disease
Received: 15 April 2002 / Accepted: 27 May 2002 / Published online: 31 July 2002
© Springer-Verlag 2002
lies represent only a small percentage of the total AD cases,
functional studies of the effects of the identified mutations
have become an important way to dissect the causes and
underlying disease mechanisms leading to AD.
Mutations in PSEN1 are responsible for 6%–18% of
the AD cases with early onset [5]. To date the majority
of the described PSEN1 mutations are missense muta-
tions, giving rise to the substitution of a single amino
acid (www.alzforum.org/members/resources/pres_muta-
tions/ and molgen-www.uia.ac.be/admutations/). It has
been speculated that most AD-related mutations result in
a gain of function. Mutations in PSEN1 alter the process-
ing of βAPP by favoring the production of potentially
toxic long-tailed β-amyloid (Aβ) peptides ending at resi-
due 42 or 43 [6]. Presenilin 1 activity is also required for
the cleavage of Notch1 at the plasma membrane and the
release of the Notch1 intracellular domain [7]. Mutations
in genes involved in Notch signaling also lead to late-
onset neurological diseases such as CADASIL [8].
Although the provisional diagnosis of AD may be
made on the basis of clinical symptoms, neuropathologi-
cal confirmation is necessary to establish a definite diag-
nosis. AD neuropathology includes the presence in the
extracellular space of amyloid plaques composed mainly
of Aβ, deposition of amyloid in the wall of blood ves-
sels, and the presence of intraneuronal neurofibrillary
tangles (NFT), consisting of hyperphosphorylated micro-
tubule-associated protein tau.
Only a few PSEN1 mutations have been described in
Latin-American [9, 10, 11] and Caribbean populations
[12]. In Cuba, a prevalence for AD of 5.13% has been
reported for the population over 60 years [13], but to
date genetic studies for AD have not been performed.
Here we describe a large Cuban family with a clinical
and neuropathological diagnosis of AD carrying a novel
PSEN1 mutation, the first to be reported in the Cuban
population.
Patients and methods
Family description
A large Cuban family with presenile dementia was ascertained
through patient IV-26 (Fig. 1A) descending from a founder (I-1) of
Spanish origin (Canary Islands) who settled in Cuba in the early
nineteenth century. We interviewed 50 people to complete family
history, genealogy, and clinical data. The pedigree consists of 281
family members within six generations, 22 patients were reported,
and a disease description was obtained for 18 patients, of whom 6
were alive and 4 were available for clinical examination. No patho-
logical studies had been performed. Medical records were available
from patient IV-26 and III-26. Segregation of the disease in the
family was consistent with an autosomal dominant mode of inherit-
ance with high penetrance (Fig. 1A). Informed consent was ob-
tained for both clinical examination and venous puncture for blood
collection. The research project was approved by the Ethics Com-
mittee at the Higher Institute of Medical Sciences in Havana, Cuba.
Clinical studies
Two independent neurologists examined 4 patients and 6 at-risk
family members, some of them with memory complaints; 9 were
admitted to hospital for a complete examination. Blood and cere-
brospinal fluid tests, electroencephalography (EEG), brain com-
puted tomographic (CT) scan, and neurophysiological tests were
performed. Neuropsychological studies, which consisted of a bat-
tery of several tests: Mini-Mental State examination [14], Wechs-
ler Memory Scale, Word List Memory test, and Wechsler Adult
Intelligence Scale (WAIS) [15], were applied. Follow-up of some
patients was necessary and a second evaluation was performed af-
ter 1 year. The NINCDS-ADRDA criteria [16] were used to estab-
lish the clinical diagnosis.
Pathology
Patient (III-26) died at the age of 73 years during the course of this
research. Neuropathological studies such as classical hematoxy-
lin/eosin staining, Bielschowsky silver impregnation, Luxol fast
blue, Congo red, and trichromic Masson techniques were carried
out on brain tissue (temporo-occipital region fixed in paraformal-
dehyde). In addition immunohistochemical studies using antibod-
ies against presenilin 1 N-terminal (dilution 1:50, from Chemicon
International), presenilin 1 C-terminal (1:100, from Santa Cruz
Biotechnology), Aβ (1:100), and ubiquitin (1:500, DAKO), AT8
(1:40, Innogenetics, SA), PHF (a gift from P. Davies), α-synuclein
(1:1,000), and prion protein (1:100, Chemicon) were performed.
Working conditions were implemented as recommended by the
manufacturers. Diagnosis based on pathology findings was ac-
cording to CERAD criteria [17].
DNA studies
Blood samples were collected from 76 family members. DNA was
isolated following standard procedures [18]. Thirty samples were
tested with fluorescently labeled markers (short tandem repeat
polymorphisms) from the CHLC Human screening set/Weber ver-
sion 6, covering AD candidate regions on chromosomes 1, 10, 12,
14, 19, and 21 [1, 3, 19, 20, 21, 22]. Additional regions where oth-
er dementia-related loci have been localized on chromosome 3
[23], 17 [24], and 20 [25] were also tested. Genomic DNA (20 ng)
was amplified in 7.5 µl PCR reaction, using 1× GeneAmp PCR
Gold buffer, 1.5 mM MgCl2, 10 pmol of each primer (forward
primer labeled with FAM, TET, or HEX), 250 µM dNTPs, and
0.4 units of AmpliTaq Gold DNA polymerase (Applied Biosys-
tems). PCR products were pooled and loaded on an ABI 377 auto-
matic DNA sequencer (6.25% denaturing FMC Long Ranger
acrylamide gel, filterset C, and GS-500XL Tamra as size stan-
dard). Data were analyzed using Genescan 3.1 and Genotyper 2.5
(updated) software from Applied Biosystems.
Haplotypes for every region were constructed based on the
minimal number of recombinations. Additional markers from the
Genethon linkage map [26] were tested for the chromosome
14q24.3 region.
Genotypes for APOE were also determined following the one-
stage PCR method described elsewhere [27]. PCR products were
digested with HhaI (10 units/µl, Life Technologies), fragments
were separated on Excell Gels (Pharmacia) using the Multiphor
electrophoresis system (Pharmacia), and visualized by silver stain-
ing. Gels were scored by two independent observers.
Linkage analysis
Simulation calculations using the SLINK and MSIM programs
[28] showed an average Lod score of 2.17 and a maximum of 5.55
at θ=0, demonstrating the family had enough statistical power to
detect genetic linkage. In our linkage analysis, AD was assumed
to be an autosomal dominant disease with a gene frequency of
0.001. Mutation rate was set equal to 0 and equal recombination
rates were assumed for males and females. Age-dependent pene-
trance was defined by five liability classes based on the ages at
onset observed in this family: unaffected at risk (<40 years old): 0,
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0, 0; 40–55 years old: 0.001, 0.5, 0.5; 56–70 years old: 0.01, 0.7,
0.7; 71–85years old: 0.01, 0.8, 0.8; married in and affected: 0, 0.9,
0.9. Equal allele frequencies for markers were assumed, since
there were no data available from the Cuban population. Two-
point linkage analysis was performed using the MLINK program
from the LINKAGE package version 5.1. Marker order and genet-
ic distances were used according to the Marshfield integrated link-
age maps (www.marshfieldclinic.org/research/genetics/).
Sequence analysis
All 12 exons from the PSEN1 gene were sequenced by the use of
intronic flanking primers as described previously [5]. For exon 2
(forward primer: 5′-TCGTGACAAATTAATACATTCC-3′) and
exon 6 (forward 5′-CAGTCTGGGCGACAAAGTG-3′ and re-
verse 5′-TTAAATGATAGCTACACAGCA-3′) we designed new
primers, further away from the exon-intron boundary (Genbank
accession no. AH004968). We also sequenced part of the regulato-
ry region, 2 kb upstream exon 1 (primer sequences published else-
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Fig. 1 A Pedigree of the family. Haplotypes corresponding to the
chromosome 14q24.3 region are shown. Filled (black) symbols re-
present demented individuals. Gender and ages are not specified
for reasons of confidentiality. A diagonal line across the symbol
means deceased individual; two diagonal lines indicate suicide.
Filled (black) bars indicate the disease haplotype. B Direct se-
quencing revealed a heterozygous base change C→A in exon 6 of
the PSEN1 gene
where [29]). Genomic DNA (50 ng) from 2 patients and 2 healthy
Cuban controls was used as template for PCR reactions. Specific
conditions were 1× PCR buffer GibcoBRL, 1.5 mM MgCl2,
200 µM dNTPs, Taq DNA Polymerase 2 units per reaction, and
25 pmol of each forward and reverse primer in 50 µl of reaction
volume. PCR product (5 µl) was checked on 1.5% agarose gel, the
rest was purified (Qiagen kit) and used for a second reaction using
the BigDye terminator kit (Applied Biosystems). Products were
loaded on an ABI 377 Automatic DNA sequencer and analyzed
with Factura and Sequence Navigator program (Applied Biosys-
tems). Once a heterozygous base change or another variation was
found in the index case, all patients and 4 healthy controls were
sequenced.
Allele-specific oligonucleotide hybridization
Sixty family members and 40 unrelated Cuban controls were test-
ed for the C→A change detected in exon 6 of the PSEN1 gene. Al-
lele-specific oligonucleotides [30] were designed for the normal
5′-ATTGTTGCTGTTCTT-3′ and mutated allele 5′-ATTGTTGA
TGTTCTT-3′ and radioactively labeled with α-dATP [31]. PCR
products from exon 6 were fixed on two nylon membranes and hy-
bridized with the normal and mutated oligonucleotide respectively,
under specific conditions (35°C 1 h). Filters were washed until a
final stringency of 0.3× SCC and 0.1% sodium dodecyl sulfate
(35°C) was reached. Membranes were exposed to X-ray films.
Results
Clinical studies
Clinical characteristics of 14 patients are shown in Ta-
ble 1. Memory impairment was the main symptom
shared by all patients. Mean age at onset was 59 years of
age, with a mean disease duration of 9 years. Patient III-
17 showed late-onset dementia (76–83 years), but with
similar clinical characteristics to the other patients. No
cases of presenile dementia have been reported among
his descendants.
The propositus, IV-26, started having problems at age
48 years when she suffered a cerebral ischemic episode.
After recovering from unconsciousness (a few minutes),
she had right hemiparesis in the face and body. The pres-
ence of any symptom before this episode could not be con-
firmed. Thereafter, she complained of memory loss, lack of
interest, she started making mistakes at work, and due to
progressive worsening of symptoms, she was admitted to
hospital. The neuropsychological studies were altered,
EEG showed slow base activity and bifrontal irritative ar-
eas, and head CT scan displayed cerebral and cerebellar at-
rophy and a hypodense lesion the in left parieto-temporal
area. At age 53 years she was unable to recognize even her
closer relatives, she was completely dependent on caregiv-
ers, and was bedridden until she died 6 years later.
In addition to the propositus, 5 relatives were reported
as patients; 3 of them were available for clinical exami-
nation (III-26, IV-24, and IV-28). Patient III-26 had a
well-established dementia with 5 years of disease evolu-
tion and was bedridden. Generalized cortical atrophy,
ventricular enlargement, and hypodense regions sugges-
tive of vascular lesions were observed on brain CT scan.
The patient died 1 year later at age 73 years.
Patient IV-24 was seen for the first time after 1 year
of disease evolution. Neuropsychological tests were
clearly altered. Patient IV-28 had a subtle alteration in
neuropsychological studies a few months after the onset
of symptoms. Follow-up of patients IV-24 and IV-28
confirmed a progressive deterioration of cognitive func-
tions with impairment of daily activities. The patients
had concentration and calculation deficits, difficulties in
immediate and delayed recall of recently presented mate-
rial, decreased emotional response, impairment of spatial
skills, delay of speech, and anosoagnosia. CT scans from
patients IV-24 and IV-28 were normal at first-time exam-
ination. A second CT scan performed 2 years later (pa-
tient IV-28) showed signs of diffuse cortical atrophy.
Other causes of dementia were excluded and the diagno-
sis of presenile dementia, probable AD was established.
Neuropathological studies
Microscopic examination of brain material (patient III-
26) revealed neuronal loss and both diffuse and core
neuritic plaques. The presence of amyloid plaques was
confirmed by immunostaining with an Aβ antibody
(Fig. 2 A and B). Cerebral amyloid angiopathy was also
observed (Fig. 2B). The existence of abundant amyloid
plaques was the most prominent feature. Tau immuno-
histochemistry (AT8 and PHF antibodies) revealed nu-
merous NFT (Fig. 2C and D, respectively). Immunohis-
tochemistry using antibodies against prion protein did
not show any difference between normal controls and
our patient. No inclusions were detected with the α-
synuclein antibody. Pathological findings provided suffi-
cient evidence to confirm the diagnosis of AD.
DNA studies
APOE genotypes
Forty-seven DNA samples were tested, 32 were homozy-
gous ε3, 13 had the ε3/ε4 genotype, and 2 were homozy-
gous ε4. Allele ε4 was only present in the second branch
of the pedigree. Of 4 tested patients, 3 had the ε3/ε4 gen-
otype.
Other genotypes
Genotypes for markers situated on chromosomal regions
1q31–42 (PSEN2), 10q24 (AD6), 12p11.23-q13.12
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Table 1 Clinical description of patients (DCF deterioration of cognitive function)
Patients
Clinical characteristics II-2a II-4a III-1a III-3a III-8a III-14a III-17a III-23a III-25a III-26 IV-20a IV-24 IV-26 IV-28
Age at onset/death 65–80 61–68 55–72 63–68 51–56 59–67 76–83 58–69 63–72 67–73 53–62 51–(56) 48–59 50–(54)
(current)
Signs and symptoms
Memory loss + + + + + + + + + + + + + +
Impairment of daily + + + + + + + + + + + + + +
activities
Altered behavior – – + + + – – + – – + + + +
Depression – – + – + + – – + – + – + –
Anxiety – – + – – – – – – – – – – +
Aggression – – + + + – – – – – – – – –
Aphasia + + – + + + + + + + + – + –
Apraxia – – – + – + + + – + + – + +
Agnosia + + – – + + + + + + + – + –
Dementia + + + + + + + + + + + DCF + DCF
Ischemic episodes – – – – – – – + – + + – + –
Gait disorder + + – + + – + – + – – – – +
Seizures – – – – – – – – – – + – + –
aBased on family history
(AD5), 14q24.3 (PSEN1), 19cen-q13.2 (AD2), and
21q21 (APP) were determined for 30 family members.
In addition, other dementia-related regions 3p11.1-q11.2
(DMT1), 17q21.1 (MAPT), and 20pter-p12 (PRNP) were
tested. Haplotype and linkage analysis allowed us to ex-
clude the presence of the gene responsible for most of
them.
Evidence supporting genetic linkage was only found
for the chromosome 14q24.3 region, two-point linkage
analysis revealed positive Lod scores for several adja-
cent markers, and a maximum Lod score of 3.79 was ob-
tained for marker D14S43 at θ=0.
We then saturated the region with additional markers
from D14S52 to D14S617 covering 50 cM. Haplotypes
from 45 family members are shown in Fig. 1. The 4 pa-
tients shared a common region spanning 9 cM from
marker D14S588 to D14S43. Patient IV-24 showed re-
combination events in both telomeric and centromeric
parts of the haplotype, allowing us to determine the up-
per and lower limit of the region shared by all 4 patients.
Several demented patients were reported to have psy-
chiatric symptoms (aggression, restlessness, anxiety, de-
pression), but did have haplotypes identical to the other
patients.
Sequencing of PSEN1
According to several genetic maps, the PSEN1 gene is
located close to markers D14S1002 and D14S77 in the
middle of our critical region. Since mutations in the pre-
senilin genes are the most common cause of the prese-
nile dementias with autosomal dominant inheritance, we
performed direct sequencing of 12 exons of PSEN1 and
part of its regulatory region for both sense and antisense
strands.
A heterozygous base substitution at position +520
from the ATG starting site, resulting in a C to A trans-
version, was found in exon 6 (Fig. 1B), which is predict-
ed to cause an amino acid change from leucine to me-
thionine in the transmembrane domain III of the presen-
ilin 1 protein. We then included additional samples; all
available DNAs from the family (60 individuals) and 40
unrelated Cuban controls were tested with allele-specific
oligonucleotides. The mutation was found to co-segre-
gate with the disease phenotype and the associated dis-
ease haplotype, and was present in 8 at-risk subjects (5
are shown in Fig. 1A), but not in other healthy individu-
als and spouses (96 chromosomes). The C→A change
was not observed in any of the 80 control chromosomes
from the general Cuban population.
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Fig. 2 Sections of temporal cortex of patient III-26, stained with
β-amyloid antibody (A and B), showing numerous extracellular
plaques and amyloid deposition in the wall of a blood vessel (B),
magnification ×200. C and D Immunostaining with AT8 and PHF
antibodies showed several neurofibrillary tangles, magnification
×400
Discussion
The clinical picture was compatible with AD except for
the fact that 4 of 18 patients had vascular episodes such
as transient ischemic crises. Cerebral amyloid angiopa-
thy (CAA) is best known as a leading cause of lobar
hemorrhages in the elderly and as a common finding in
AD. It has also been implicated in the production of oth-
er cerebrovascular lesions [32]. The presence of CAA
might explain the vascular episodes described in patients
III-23, III-26, IV-20, and IV-26. Hypodense zones sug-
gestive of vascular lesions were observed on CT scans
from patients III-26 and IV-26; in addition, amyloid de-
posits were present in the wall of brain blood vessels
(patient III-26), confirming the presence of CAA.
Factors such as the vasoactive character of Aβ, which
can produce vasospasm in vitro at low concentrations
[31], the secretion of Aβ by activated human platelets
[33], and the hyaline necrosis surrounding the amyloid
deposit in the vessel wall [34] have been postulated as
possible mechanisms by which amyloid in the vessels
can lead to vascular lesions.
Furthermore, a relationship between APOE ε4 allele
and the presence of CAA and cerebrovascular pathology
in AD has been suggested, since the APOE ε4 allele is a
risk factor for the development of CAA in AD [35]. In
this family, available patients with ischemic episodes
also carry the APOE ε4 allele (patients III-26 and IV-26).
We found significant evidence for genetic linkage to
chromosome 14q24.3. We were able to reconstruct
haplotypes for 11 deceased patients using first-degree
relatives; all of them had the same “disease haplotype”,
except 1 patient (III-17) in which the reconstructed hap-
lotype was different. This patient showed a much later
disease onset (76 years old), while the observed range in
the other patients was 48–67 years old. Unfortunately,
only family history but no medical records were avail-
able. It might be that this patient had dementia due to
other causes, and therefore could be a phenocopy. Coex-
istence of both early onset (with an associated PSEN1
mutation) and late-onset forms of AD in the same family
has been reported before [36].
Several heterozygous base changes were detected
during PSEN1 sequencing, but none of the sequence al-
terations was found to co-segregate with the disease ex-
cept the C520A change. Several facts indicate the patho-
genicity of this novel PSEN1 mutation. The C520A
change was present in all examined patients and in all
relatives carrying the disease haplotype, although they
were still below the age at onset of AD in the family.
The C→A change is unlikely to be a common polymor-
phism, we did not find it in 80 control chromosomes
(from the same population) or in unaffected relatives (96
chromosomes) that did not carry the disease haplotype.
L174 M is a conservative amino acid substitution
since leucine and methionine are both nonpolar amino
acids. Nevertheless, close to half of the PSEN1 and
PSEN2 reported mutations also lead to the same type of
amino acid change. The leucine at position 174 of the
presenilin 1 protein is highly conserved among different
species (Fig. 3) and between homologous proteins like
presenilin 2 and sel-12, indicating that this position
(TMIII) is important for protein function. Adjacent ami-
no acid positions at 163, 165, 166, 169, 171, 173, and
184, where other mutations have been found, are also
evolutionary conserved.
Under normal conditions presenilin 1 holoprotein is
rapidly converted into two fragments, an amino terminal
fragment (NTF) and a carboxy terminal fragment (CTF)
[37]. Presenilin 1 fragments can associate into tightly
bound complexes that may represent the principal form
in which presenilin functions in cells [38]. Formation of
these high molecular weight complexes composed of
both presenilin 1 fragments may also explain why FAD-
associated mutations within the N-terminal region of
presenilin 1 (like L174 M) result in the hyperaccumula-
tion not only of the NTF but also of the CTF. It has been
proposed that the observed elevation in the accumulated
amounts of mutant presenilin 1 NTFs and CTFs must be
the result of enhanced endoproteolytic processing of mu-
tant presenilin 1 protein and/or greater stability of mu-
tant presenilin 1-derived fragments [39], which appears
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Fig. 3 Alignment of human presenilin 1, presenilin 2, and ortho-
logous protein fragments. Highly conserved amino acids are
shown in boxes. Leucine at position 174 is substantially conserved
across several species. Asterisks indicate where other PSEN1 mu-
tations are located
to be associated with enhanced production of Aβ42 and
early onset FAD.
Another possible mode of action of the L174 M muta-
tion might be that of an alternative translation start site.
From the 82 mutations described in PSEN1, only V94 M
in exon 4 [9] and the current mutation (exon 6) introduce
a new methionine in the protein sequence.
Functional assays will be required to determine
whether the L174 M mutation affects presenilin 1 protein
activity for the cleavage of Notch1 at the plasma mem-
brane and the release of the Notch1 intracellular domain.
In conclusion, we found a novel PSEN1 mutation in a
large family with clinical and pathological diagnosis of
early onset FAD. This is the first genetic study on AD that
identifies the involvement of the PSEN1 gene in Cuba.
L174 M is the seventh mutation described in Latin-
American and Caribbean populations; for some of them
(Colombia and Dominican Republic) a founder effect
has been described. We are currently in the process of
collecting new familial and sporadic cases with early on-
set AD. It will be of interest to investigate the contribu-
tion of this mutation to other early onset AD cases with-
in the Cuban population or in others of Hispanic origin.
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